!""#"$%#& '()*&%& *+,-,.&,/(01&-+*2&,*0345*6&780&9:08+*(2&'(;*216&
!""#"$%#& - - PowerPoint PPT Presentation
!""#"$%#& - - PowerPoint PPT Presentation
!""#"$%#& *+,-,.&,/(01&-+*2&,*0345*6&780&9:08+*(2&'(;*216& '()*&%& From strategies to services eHealth as the enabler for cross- border healthcare From Strategies to Services
From strategies to services – eHealth as the enabler for cross- border healthcare
From Strategies to Services
- !
Provide concrete cross border services that ensure safe, secure and efficient medical treatment for citizens when travelling across Europe
- !
Focus on services close to the patient: –! Patient Summary for EU Citizens
- ! Occasional Visit
- ! Regular Visit
–! ePrescribing for EU Citizens
- ! Medication Re-dispense
- ! Medication Occasional Dispense
- !
Build on existing National eHealth Projects and use experiences and knowledge from all Member States
- ! Healthcare a strict national prerogative
- ! Previously only limited co-operation on a general policy level
- ! Substantial variations between national healthcare systems, but
also similar challenges are faced and….
- ! …substantial similarities in political ambitions to reform
healthcare as well as in the challenges to reach these goals
- ! The work started in 2003-2006 at the Ministerial Conferences
- ! In 2004 the eHealth Action Plan was adopted and the I2010 was
created
- ! And in 2007 in Berlin the eHealth Initiative was created.…
Closer Cooperation on Healthcare
a new era in legal and policy framework for EU Cooperation on eHealth
- ! Proposal for a European Directive on patients’ rights in cross-
border healthcare
- ! Commission Recommendation on cross-border interoperability of
electronic health record systems
- ! Communication on telemedicine for the benefit of patients,
healthcare systems and society
- ! eHealth Standardisation Mandate 403
2008 a New Era
- ! Goal for the epSOS eHealth Project:
–! “to develop a practical eHealth framework and ICT infrastructure that will enable secure access to patient health information, particularly with respect to a basic patient summary and ePrescription, between European healthcare systems”
- ! Challenges to get there:
–! Legal Interoperability –! Organisational Interoperability –! Semantic Interoperability –! Technical Interoperability
Goals & Challenges
<=*&'08>*51&<*(/&58264616&87&!?&@*2*A54(04*6&708/&%!& /*/@*0&61(1*6B&!"#$%&#$'(#$')#$(*#$(+#$,-#$."#$/*#$+)#$ +($012$345$6)$& –!#&C(;82(D&E4246104*6&87&F*(D1=G%H&C(;82(DI 0*)482(D&J8/+*1*25*&J*21*06K&$ –!J8/+*1*25*&J*21*06&L25D:M42)IN80O42)&N41=&D85(D& 80)(24P(;826&N41=&1=8:6(2M6&87&J82104@:1806& –!LF9.9:08+*&0*+0*6*2;2)&LJ<&42M:610Q&1*(/&
The Pilot Team
The Industry team
78$ !99513:;5$$ !<=0$>50?34%0;5$$ !@A??A$ B;CDE4$"5?59AF$$ %CE9A$$ %8G$852C90$$ %:E3A2CH$$ 2I8ADA1$$ '520?:E$$ (?593;A1C9$-59A;2$%AF@01J$$ (".!8$$ K($>50?3490;5$$ K1AFA1$$ .%L$$ .12;0$ .1=A153$$ .1EC5?$$ .135?$%A;@A;0DA1$+M!M$$ *AFI0;2C0$.1=A;F0D90$$ 8C9;AEAN$$ /53EF0;3$$ O;09?5$$ GAE0F$$
- .+($$
+C15:;0$+@!$$ +F0;3.+$$ +35;C0$8:FF5;3$%A1E:?D1<$!K$$ "C01CP+@C;C3$$ ";5I?58$ "P+JE35FE$ QP351DA1$
EU memberstate (not participating) Non EU country Single (national) patient identifier Multiple (regional) patient identifiers
Availability of Patient identifier 2008
EU memberstate (not participating) Non EU country Single (national) patient identifier Multiple (regional) patient identifiers
Availability of Patient Identifier 2010
Nationally-led Regionally-led Not available / unknown EU memberstate (not participating) Non EU country Fully available Partly available Fully available Partly available
HCP/HCPO Identifier – Suitability for Authentication & Digital signing 2008
Nationally-led Regionally-led Not available / unknown EU memberstate (not participating) Non EU country Fully available Partly available Fully available Partly available
HCP/HCPO Identifier – Suitability for Authentication & Digital signing 2010
Nationally-led Regionally-led Not available / unknown EU memberstate (not participating) Non EU country Fully available Partly available Fully available Partly available
Availability of opt-out Consent 2008
Nationally-led Regionally-led Not available / unknown EU memberstate (not participating) Non EU country Fully available Partly available Fully available Partly available Opt-out likely to be implemented
Availability of opt-out consent 2010
Nationally available & operational Regionally available & operational Not available / unknown EU memberstate (not participating) Non EU country >25% <25% >25% <25%
Availability of Patient Summary 2008
Nationally available & operational Regionally available & operational Not available / unknown EU memberstate (not participating) Non EU country >25% <25% >25% <25%
Availability of Patient Summary 2010
Nationally available & operational Regionally available & operational Not available / unknown EU memberstate (not participating) Non EU country >25% <25% >25% <25%
Availability of ePrescriptions 2008
Nationally available & operational Regionally available & operational Not available / unknown EU memberstate (not participating) Non EU country >25% <25% >25% <25%
Availability of ePrescriptions 2010
Nationally available & operational Regionally available & operational Not available / unknown EU memberstate (not participating) Non EU country >25% <25% >25% <25%
Availability of Dispense Information 2008
Nationally available & operational Regionally available & operational Not available / unknown EU memberstate (not participating) Non EU country >25% <25% >25% <25%
Availability of Dispense Information 2010
Nationally available & operational Regionally available & operational Not available / unknown EU memberstate (not participating) Non EU country >25% <25% >25% <25%
Availability of Medication Summary 2008
Nationally available & operational Regionally available & operational Not available / unknown EU memberstate (not participating) Non EU country >25% <25% >25% <25%
Availability of Medication Summary 2010
LC34A:3$0R5F@D1<$3A$C135;S515$C1$345$ 5HCED1<$$8+$?5<0?$=;0F5TA;UEM$!1$ V5@+O+$?5<0?$C135;A@5;0IC?C3J$?0J5;W$ CE$9;50352M$ XM! @;ASCECA1E$=A;$022;5EEC1<$0??$ 5EE51D0?$*Y-$;5Z:C;5F513E$A=$ 8+$0E$@0;3$A=$345$25EC<1$[$$ \M! E:94$@;ASCECA1E$0;5$3;01E?0352$ C13A$EJE35F$012$E5;SC95$ E@59C]90DA1E$^E0=5<:0;2E_$ 7M! !@@?C90DA1$A=$E0=5<:0;2E$CE$ 0:2C30I?5$`$)5J$-A?5$A=$/%GE$
Legal Interoperability
80C1$.EE:5E$ *5<0?$ %5;30C13J$ 5@+O+$ !@@;A094$ 80C1$%40??51<5$ (H@59352$.F@093$
'030$G;A359DA1$ 012$%A1]251D0?C3J$
+:a9C513$ =525;0D1<$ 10DA10?$3;:E3$ EJE35FE$ (6$?5S5?$.1=A;F0DA1$ KAS5;10195$ 3AT0;2E$ 40;FA1Cb0DA1$A=$ @;09D95$
>50?34$+JE35FE$
*AT$ 5@+O+$ @A?C9C5E$012$ E0=5<:0;2E$ E59:;5$9A??0IA;0DA1$ TC34$?A90?$0:34A;CD5E$ "AT0;2E$0995?5;0D1<$ 345$25@?AJF513$A=$ ;5CFI:;E0I?5$5>50?34$ 9;AEE$IA;25;$E5;SC95E$
G;A=5EECA10?$ 0E@593E$012$EA9C0?$ 9A135H3$$
*AT$ 9A:13;J$A=$ 3;503F513$ ;:?5E$0@@?J$ (H@?A;5$@;A=5EECA10?$ ;C<43E$C1$345$9A135H3$A=$ 9;AEE$IA;25;$90;5$ "AT0;2E$?5<0?$ 95;30C13J$A1$ @;A=5EECA10?E$;C<43E$C1$ 345$I;A025;$9A135H3$ 5M<M$$35?5F52C9C15$
*C0IC?C3J$
*AT$ 5?0IA;0DA1$ A=$E@59C]9$ E0=5<:0;2E$$ 9A??0IA;0DA1$TC34$(6$ ?5S5?$@;A=5EECA10?$ 0EEA9C0DA1E#$012$ E30U54A?25;E$ "AT0;2E$F:3:0?$ ;59A<1CDA1$
Legal Issues: Summary of findings
<=*&R*D43*0*M& –! L24;(D&,58+*& –! S*)(D&T&U*):D(180Q&J82610(4216& –! U*+801&82&-++801:24;*6&(2M&J82610(4216&87&+(0;54+(;2)&E,& –! R466*/42(;82&J825*+1&(2M&'D(2& –! 93(D:(;82&E*1=8M8D8)Q&(2M&'D(2& –! U*346*M&'08>*51&'D(2& –! R0(V&R*A24;82&87&8+*0(;82(D&,*0345*&U*W:40*/*216.& *'0*6504+;82& –! R0(V&R*A24;82&87&8+*0(;82(D&,*0345*&U*W:40*/*216&X& '(;*21&,://(0Q&
Where are we at?
<=*&R*D43*0(@D*6&18&@*&R*D43*0*M&(1&1=*&*2M&87&1=*&Q*(0&18&1=*& J8//466482$& –! ,*5:041Q&6*0345*6&6+*54A5(;82&M*A24;82& –! LM*2;1Q&/(2()*/*21&6*0345*6&6+*54A5(;82&M*A24;82& –! R0(V&*+,-,&6Q61*/&1*5=245(D&6+*54A5(;82& –! ,*/(2;5&,*0345*6&M*A24;82& –! J8//82&J8/+82*216&,+*54A5(;82& –! <*61&,5*2(0486&(2M&,41*&J=845*& –! R0(V&C(;82(D&'4D81&,*1:+&(2M&R*+D8Q/*21&):4M*& –! L21*08+*0(@4D41Q&70(/*N80O& –! ,1(2M(0M&J8210(516&1*0/6&780&E,&M85:/*21&780&*2)()*/*21& 87&+4D816&
What is next?
Overall Project Plan
- !
Asking for approval of D5.2.2 Revised Project plan:
- ! Conclusion after analysis and re-planning: Extension of project duration by 6
months
<=*&'08>*51&<*(/&58264616&87&!?&@*2*A54(04*6&708/&%!& /*/@*0&61(1*6B&!"#$%&#$'(#$')#$(*#$(+#$,-#$."#$/*#$+)#$ +($012$345$6)$& F(3*&780/(DDQ&(6O*M&18&>842& –!961824(& –!Y42D(2M& –!L5*D(2M& –!,D83*24(& –!'801:)(D&
F(3*&>842*M&J(DD48+*&
–!C80N(Q&& –!,N41P*0D(2M&
Where are we at?
- ! J8//:245(;82&N41=&(&@08(M*0&(:M4*25*&42&@81=&M40*5;826&&
- ! L270(610:51:0*&780&M466*/42(;82&(5;34;*6&&
- ! Z:(D4A*M&7**M@(5O&&
- ! L2+:1&708/&J(DD48+*[6&M*A2*M&(0*(6&87&N80O&\U8(M/(+G&9].
0*58//*2M(;826G&,1(2M(0M6^&
http://www.calliope-network.eu/
Mikael Erlandsson
Cooperation is Necessary
!""""$"$& _%& *+,-,&X&,/(01&-+*2&,*0345*6&780&9:08+*(2&'(;*216&